SG10201607968WA - Artificial nucleic acid molecules for improved protein or peptide expression - Google Patents
Artificial nucleic acid molecules for improved protein or peptide expressionInfo
- Publication number
- SG10201607968WA SG10201607968WA SG10201607968WA SG10201607968WA SG10201607968WA SG 10201607968W A SG10201607968W A SG 10201607968WA SG 10201607968W A SG10201607968W A SG 10201607968WA SG 10201607968W A SG10201607968W A SG 10201607968WA SG 10201607968W A SG10201607968W A SG 10201607968WA
- Authority
- SG
- Singapore
- Prior art keywords
- nucleic acid
- acid molecules
- artificial nucleic
- peptide expression
- improved protein
- Prior art date
Links
- 108020004707 nucleic acids Proteins 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/52—Methods for regulating/modulating their activity modulating the physical stability, e.g. GC-content
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
- C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2012001336 | 2012-03-27 | ||
EP2012002447 | 2012-06-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201607968WA true SG10201607968WA (en) | 2016-12-29 |
Family
ID=48128253
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201710631RA SG10201710631RA (en) | 2012-03-27 | 2013-03-27 | Artificial nucleic acid molecules for improved protein or peptide expression |
SG10201607968WA SG10201607968WA (en) | 2012-03-27 | 2013-03-27 | Artificial nucleic acid molecules for improved protein or peptide expression |
SG11201403450VA SG11201403450VA (en) | 2012-03-27 | 2013-03-27 | Artificial nucleic acid molecules for improved protein or peptide expression |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201710631RA SG10201710631RA (en) | 2012-03-27 | 2013-03-27 | Artificial nucleic acid molecules for improved protein or peptide expression |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201403450VA SG11201403450VA (en) | 2012-03-27 | 2013-03-27 | Artificial nucleic acid molecules for improved protein or peptide expression |
Country Status (13)
Country | Link |
---|---|
US (3) | US9683233B2 (ru) |
JP (2) | JP6185553B2 (ru) |
KR (1) | KR102287184B1 (ru) |
CN (1) | CN104284979B (ru) |
AU (2) | AU2013242404B2 (ru) |
BR (1) | BR112014018210A2 (ru) |
CA (1) | CA2859452C (ru) |
DK (2) | DK3578659T3 (ru) |
ES (3) | ES2654205T3 (ru) |
MX (2) | MX2019002345A (ru) |
RU (2) | RU2658490C2 (ru) |
SG (3) | SG10201710631RA (ru) |
WO (1) | WO2013143699A1 (ru) |
Families Citing this family (162)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
CN104531671A (zh) | 2010-10-01 | 2015-04-22 | 现代治疗公司 | 设计核酸及其使用方法 |
WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
IL280771B2 (en) | 2011-06-08 | 2024-03-01 | Shire Human Genetic Therapies | Preparations of lipid nanoparticles and methods for administration of mRNA |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
ES2923757T3 (es) | 2011-12-16 | 2022-09-30 | Modernatx Inc | Composiciones de ARNm modificado |
WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
CN104284979B (zh) | 2012-03-27 | 2018-06-08 | 库瑞瓦格股份公司 | 用于提高的蛋白或肽表达的人工核酸分子 |
CN108929880A (zh) | 2012-03-27 | 2018-12-04 | 库瑞瓦格股份公司 | 包含5′toputr的人工核酸分子 |
SG11201405542UA (en) | 2012-03-27 | 2014-10-30 | Curevac Gmbh | Artificial nucleic acid molecules |
AU2013243953A1 (en) | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
DK2922554T3 (en) | 2012-11-26 | 2022-05-23 | Modernatx Inc | Terminalt modificeret rna |
SG11201506052PA (en) | 2013-02-22 | 2015-09-29 | Curevac Gmbh | Combination of vaccination and inhibition of the pd-1 pathway |
EP2968391A1 (en) * | 2013-03-13 | 2016-01-20 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
LT2972360T (lt) | 2013-03-15 | 2018-09-10 | Translate Bio, Inc. | Sinergistinis nukleorūgščių pristatymo padidinimas sumaišytų kompozicijų pagalba |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
AU2014310931B2 (en) | 2013-08-21 | 2019-12-19 | CureVac SE | Rabies vaccine |
WO2015024669A1 (en) | 2013-08-21 | 2015-02-26 | Curevac Gmbh | Combination vaccine |
SG10201801428RA (en) * | 2013-08-21 | 2018-03-28 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
CN105473158B (zh) | 2013-08-21 | 2021-04-13 | 库瑞瓦格股份公司 | 呼吸道合胞病毒(rsv)疫苗 |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
WO2015051214A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
ES2806575T3 (es) | 2013-11-01 | 2021-02-18 | Curevac Ag | ARN modificado con propiedades inmunoestimuladoras disminuidas |
SG10201805660WA (en) | 2013-12-30 | 2018-08-30 | Curevac Ag | Methods for rna analysis |
RU2717986C2 (ru) * | 2013-12-30 | 2020-03-27 | Куревак Аг | Искусственные молекулы нуклеиновой кислоты |
US11254951B2 (en) | 2014-12-30 | 2022-02-22 | Curevac Ag | Artificial nucleic acid molecules |
WO2015101415A1 (en) | 2013-12-30 | 2015-07-09 | Curevac Gmbh | Artificial nucleic acid molecules |
EP3495486B1 (en) * | 2013-12-30 | 2020-12-16 | CureVac AG | Artificial nucleic acid molecules |
WO2015135558A1 (en) | 2014-03-12 | 2015-09-17 | Curevac Gmbh | Combination of vaccination and ox40 agonists |
WO2015149944A2 (en) | 2014-04-01 | 2015-10-08 | Curevac Gmbh | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
ES2727776T3 (es) | 2014-06-10 | 2019-10-18 | Curevac Ag | Método para mejorar la producción de ARN |
RS63848B1 (sr) | 2014-06-25 | 2023-01-31 | Acuitas Therapeutics Inc | Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina |
WO2016022947A1 (en) | 2014-08-07 | 2016-02-11 | The Johns Hopkins University | Nanoparticle modification of human adipose-derived mesenchymal stem cells for treating brain cancer and other neurological diseases |
JP6824594B2 (ja) | 2014-09-11 | 2021-02-03 | Jnc株式会社 | 合成遺伝子の設計方法 |
PT3708668T (pt) * | 2014-12-12 | 2022-09-14 | Curevac Ag | Moléculas de ácido nucleico artificiais para uma expressão melhorada de proteína |
MX2017008670A (es) * | 2014-12-30 | 2017-10-11 | Curevac Ag | Moleculas artificiales de acido nucleico novedosas. |
US10653768B2 (en) | 2015-04-13 | 2020-05-19 | Curevac Real Estate Gmbh | Method for producing RNA compositions |
EP4026568A1 (en) | 2015-04-17 | 2022-07-13 | CureVac Real Estate GmbH | Lyophilization of rna |
DK3326641T3 (da) | 2015-04-22 | 2019-09-30 | Curevac Ag | Rna-holdig sammensætning til behandling af tumorsygdomme |
US11384375B2 (en) | 2015-04-30 | 2022-07-12 | Curevac Ag | Immobilized poly(n)polymerase |
WO2016180430A1 (en) | 2015-05-08 | 2016-11-17 | Curevac Ag | Method for producing rna |
US11559570B2 (en) | 2015-05-15 | 2023-01-24 | CureVac SE | Prime-boost regimens involving administration of at least one mRNA construct |
EP3297682B1 (en) | 2015-05-20 | 2021-07-14 | CureVac AG | Dry powder composition comprising long-chain rna |
US10517827B2 (en) | 2015-05-20 | 2019-12-31 | Curevac Ag | Dry powder composition comprising long-chain RNA |
DE202016009003U1 (de) | 2015-05-29 | 2021-05-28 | Curevac Real Estate Gmbh | Zusammensetzung umfassend in vitro transkribierte RNA erhältlich durch ein Verfahren zur Herstellung und Reinigung von RNA mit mindestens einem Schritt mit einer tangentialen Flussfiltration |
EP4098743A1 (en) | 2015-05-29 | 2022-12-07 | CureVac AG | Method for adding cap structures to rna using immobilized enzymes |
CN107922364B (zh) | 2015-06-29 | 2021-12-31 | 爱康泰生治疗公司 | 用于递送核酸的脂质和脂质纳米颗粒制剂 |
US10501768B2 (en) | 2015-07-13 | 2019-12-10 | Curevac Ag | Method of producing RNA from circular DNA and corresponding template DNA |
MX2018001040A (es) * | 2015-08-28 | 2018-06-15 | Curevac Ag | Moleculas de acido nucleico artificiales. |
LT3350157T (lt) | 2015-09-17 | 2022-02-25 | Modernatx, Inc. | Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu |
WO2017059902A1 (en) * | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
EP3362576A1 (en) | 2015-10-12 | 2018-08-22 | CureVac AG | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
WO2017066781A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified phosphate linkage |
WO2017066789A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified sugar |
WO2017066791A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Sugar substituted mrna cap analogs |
JP2018530587A (ja) | 2015-10-16 | 2018-10-18 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | mRNAキャップ類似体およびmRNAキャッピングの方法 |
WO2017066782A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Hydrophobic mrna cap analogs |
JP7030690B2 (ja) | 2015-10-28 | 2022-03-07 | アキィタス・セラピューティクス・インコーポレイテッド | 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤 |
EP3373965A1 (en) | 2015-11-09 | 2018-09-19 | CureVac AG | Rotavirus vaccines |
KR20180107109A (ko) | 2015-12-22 | 2018-10-01 | 큐어백 아게 | Rna 분자 조성물의 제조 방법 |
EP4036079A3 (en) | 2015-12-22 | 2022-09-28 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of agents |
US11248223B2 (en) | 2015-12-23 | 2022-02-15 | Curevac Ag | Method of RNA in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof |
MX2018009917A (es) | 2016-02-17 | 2019-08-14 | Curevac Ag | Vacuna contra el virus del zika. |
US11920174B2 (en) | 2016-03-03 | 2024-03-05 | CureVac SE | RNA analysis by total hydrolysis and quantification of released nucleosides |
WO2017162265A1 (en) | 2016-03-21 | 2017-09-28 | Biontech Rna Pharmaceuticals Gmbh | Trans-replicating rna |
DK3440206T3 (da) | 2016-04-08 | 2020-11-23 | Translate Bio Inc | Multimer-kodende nukleinsyre og anvendelser deraf |
US20190284249A1 (en) * | 2016-04-25 | 2019-09-19 | Evorx Technologies, Inc. | Beta-catenin barcoded peptides |
US11596699B2 (en) | 2016-04-29 | 2023-03-07 | CureVac SE | RNA encoding an antibody |
EP3452493A1 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Nucleic acid molecules and uses thereof |
EP3452101A2 (en) | 2016-05-04 | 2019-03-13 | CureVac AG | Rna encoding a therapeutic protein |
EP3468613A1 (en) | 2016-06-09 | 2019-04-17 | CureVac AG | Hybrid carriers for nucleic acid cargo |
US10835583B2 (en) | 2016-06-13 | 2020-11-17 | Translate Bio, Inc. | Messenger RNA therapy for the treatment of ornithine transcarbamylase deficiency |
JP2019525901A (ja) | 2016-06-14 | 2019-09-12 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 脂質ナノ粒子の安定化製剤 |
EP3481430A4 (en) | 2016-07-11 | 2020-04-01 | Translate Bio Ma, Inc. | NUCLEIC ACID CONJUGATES AND USES THEREOF |
EP3538067A1 (en) | 2016-11-08 | 2019-09-18 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
WO2018087276A1 (en) | 2016-11-10 | 2018-05-17 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Or10h1 modulators and uses thereof |
WO2018096179A1 (en) | 2016-11-28 | 2018-05-31 | Curevac Ag | Method for purifying rna |
JP2019535839A (ja) | 2016-11-29 | 2019-12-12 | ピュアテック ヘルス エルエルシー | 治療剤の送達のためのエクソソーム |
JP2020501545A (ja) * | 2016-12-08 | 2020-01-23 | キュアバック アーゲー | 肝疾患の処置または予防のためのrna |
WO2018104540A1 (en) | 2016-12-08 | 2018-06-14 | Curevac Ag | Rnas for wound healing |
US11141476B2 (en) | 2016-12-23 | 2021-10-12 | Curevac Ag | MERS coronavirus vaccine |
WO2018115507A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Henipavirus vaccine |
US11464847B2 (en) | 2016-12-23 | 2022-10-11 | Curevac Ag | Lassa virus vaccine |
CN108456669B (zh) * | 2017-02-20 | 2023-08-08 | 上海凯赛生物技术股份有限公司 | 一种核糖体结合位点、重组表达质粒、转化子及其应用 |
EP3595727A1 (en) | 2017-03-15 | 2020-01-22 | ModernaTX, Inc. | Lipid nanoparticle formulation |
CN110520409A (zh) | 2017-03-15 | 2019-11-29 | 摩登纳特斯有限公司 | 用于细胞内递送治疗剂的化合物和组合物 |
CN110914433A (zh) | 2017-03-24 | 2020-03-24 | 库尔维科公司 | 编码crispr相关蛋白质的核酸及其用途 |
US11357856B2 (en) | 2017-04-13 | 2022-06-14 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
US11596679B2 (en) | 2017-04-27 | 2023-03-07 | Vanderbilt University | Hepatitis C virus gene sequences and methods of use therefor |
AU2018256877B2 (en) | 2017-04-28 | 2022-06-02 | Acuitas Therapeutics, Inc. | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
US20210198200A1 (en) | 2017-06-14 | 2021-07-01 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
EP3638215A4 (en) | 2017-06-15 | 2021-03-24 | Modernatx, Inc. | RNA FORMULATIONS |
CN111328287A (zh) | 2017-07-04 | 2020-06-23 | 库瑞瓦格股份公司 | 新型核酸分子 |
WO2019036008A1 (en) | 2017-08-16 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
WO2019036030A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS |
WO2019036028A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
WO2019036638A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | METHODS FOR PREPARING MODIFIED RNA |
WO2019038332A1 (en) | 2017-08-22 | 2019-02-28 | Curevac Ag | VACCINE AGAINST BUNYAVIRUS |
MX2020002348A (es) | 2017-08-31 | 2020-10-08 | Modernatx Inc | Métodos de elaboración de nanopartículas lipídicas. |
RU2020115287A (ru) * | 2017-10-19 | 2021-11-19 | Куревак Аг | Новые молекулы искусственных нуклеиновых кислот |
WO2019092153A1 (en) | 2017-11-08 | 2019-05-16 | Curevac Ag | Rna sequence adaptation |
WO2019112489A1 (en) * | 2017-12-05 | 2019-06-13 | Limited Liability Company "Gero" | Methods and agents for treatment of aging and aging related conditions and diseases |
US11931406B2 (en) | 2017-12-13 | 2024-03-19 | CureVac SE | Flavivirus vaccine |
EP3727428A1 (en) | 2017-12-20 | 2020-10-28 | Translate Bio, Inc. | Improved composition and methods for treatment of ornithine transcarbamylase deficiency |
EP3728634A1 (en) | 2017-12-21 | 2020-10-28 | CureVac AG | Linear double stranded dna coupled to a single support or a tag and methods for producing said linear double stranded dna |
EP3508499A1 (en) | 2018-01-08 | 2019-07-10 | iOmx Therapeutics AG | Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof |
CN112639107A (zh) * | 2018-06-25 | 2021-04-09 | 阿库斯股份有限公司 | 治疗clrn1相关的听力损失和/或视力损失的方法 |
WO2020061367A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
EP3852728A1 (en) | 2018-09-20 | 2021-07-28 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
AU2019370629A1 (en) * | 2018-10-29 | 2021-05-20 | Ottawa Hospital Research Institute | Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof |
JP2022523117A (ja) | 2019-01-31 | 2022-04-21 | モデルナティエックス インコーポレイテッド | ボルテックスミキサならびにその関連する方法、システム、及び装置 |
KR20210135494A (ko) | 2019-01-31 | 2021-11-15 | 모더나티엑스, 인크. | 지질 나노입자의 제조 방법 |
CN110229226B (zh) * | 2019-05-23 | 2023-04-11 | 西安医学院 | 一种slfn11截断肽及其应用和药物组合物 |
EP3987027A1 (en) * | 2019-06-24 | 2022-04-27 | ModernaTX, Inc. | Endonuclease-resistant messenger rna and uses thereof |
JP2022538688A (ja) | 2019-07-05 | 2022-09-05 | イオックス セラピューティクス アーゲー | IGSF11(VSIG3)のIgC2に結合する抗体及びその使用 |
CN112618711B (zh) * | 2019-09-24 | 2023-09-29 | 华南理工大学 | 一种猪口服接种疫苗纳米复合佐剂及其制备方法与应用 |
EP4047084A4 (en) * | 2019-10-17 | 2024-01-17 | Univ Nagoya City Public Univ Corp | ARTIFICIALLY SYNTHESIZED MRNA AND USE THEREOF |
EP3822288A1 (en) | 2019-11-18 | 2021-05-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof |
CN112980877A (zh) * | 2019-12-12 | 2021-06-18 | 中国科学院大连化学物理研究所 | 一种提高外源基因表达效率的方法 |
US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
US11576966B2 (en) | 2020-02-04 | 2023-02-14 | CureVac SE | Coronavirus vaccine |
CN111118018B (zh) * | 2020-03-05 | 2021-06-01 | 泰州博莱得利生物科技有限公司 | 猫血清白蛋白重组蛋白及其在毕赤酵母中的表达方法 |
JP2023529522A (ja) | 2020-04-09 | 2023-07-11 | スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド | 脂質ナノ粒子組成物 |
WO2021204179A1 (en) | 2020-04-09 | 2021-10-14 | Suzhou Abogen Biosciences Co., Ltd. | Nucleic acid vaccines for coronavirus |
GB2594365B (en) | 2020-04-22 | 2023-07-05 | BioNTech SE | Coronavirus vaccine |
JP2023532707A (ja) | 2020-06-30 | 2023-07-31 | スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド | 脂質化合物及び脂質ナノ粒子組成物 |
EP4175668A1 (en) | 2020-07-06 | 2023-05-10 | iOmx Therapeutics AG | Antibodies binding igv of igsf11 (vsig3) and uses thereof |
EP4182297A1 (en) | 2020-07-16 | 2023-05-24 | Acuitas Therapeutics, Inc. | Cationic lipids for use in lipid nanoparticles |
US20230279408A1 (en) * | 2020-08-07 | 2023-09-07 | The Hong Kong University Of Science And Technology | Compositions and methods for increasing protein expression |
JP2023537887A (ja) | 2020-08-20 | 2023-09-06 | スージョウ・アボジェン・バイオサイエンシズ・カンパニー・リミテッド | 脂質化合物及び脂質ナノ粒子組成物 |
US10947552B1 (en) | 2020-09-30 | 2021-03-16 | Alpine Roads, Inc. | Recombinant fusion proteins for producing milk proteins in plants |
CA3191387A1 (en) | 2020-09-30 | 2022-04-07 | Nobell Foods, Inc. | Recombinant milk proteins and food compositions comprising the same |
US10894812B1 (en) | 2020-09-30 | 2021-01-19 | Alpine Roads, Inc. | Recombinant milk proteins |
AU2021374803A1 (en) | 2020-11-03 | 2023-06-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies |
CA3205569A1 (en) | 2020-12-22 | 2022-06-30 | CureVac SE | Rna vaccine against sars-cov-2 variants |
CN116615472A (zh) | 2021-01-14 | 2023-08-18 | 苏州艾博生物科技有限公司 | 聚合物缀合的脂质化合物和脂质纳米颗粒组合物 |
WO2022152109A2 (en) | 2021-01-14 | 2022-07-21 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
EP4301402A1 (en) | 2021-03-03 | 2024-01-10 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Bispecific antibodies enhancing cell mediated immune responses |
EP4204390A1 (en) | 2021-05-24 | 2023-07-05 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
CN113904733B (zh) * | 2021-08-18 | 2022-09-13 | 国网浙江省电力有限公司信息通信分公司 | 基于基因编码与突变的超长距光传输方法及系统 |
WO2023044333A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Cyclic lipids and methods of use thereof |
TW202325263A (zh) | 2021-09-14 | 2023-07-01 | 美商雷納嘉德醫療管理公司 | 非環狀脂質及其使用方法 |
AR127312A1 (es) | 2021-10-08 | 2024-01-10 | Suzhou Abogen Biosciences Co Ltd | Compuestos lipídicos ycomposiciones de nanopartículas lipídicas |
CN116064598B (zh) | 2021-10-08 | 2024-03-12 | 苏州艾博生物科技有限公司 | 冠状病毒的核酸疫苗 |
WO2023056917A1 (en) | 2021-10-08 | 2023-04-13 | Suzhou Abogen Biosciences Co., Ltd. | Lipid compounds and lipid nanoparticle compositions |
CN113943750B (zh) * | 2021-10-16 | 2024-04-30 | 温州医科大学 | 一种秀丽隐杆线虫转基因质粒、转基因秀丽隐杆线虫的构建方法及应用 |
CN115404238A (zh) * | 2021-12-22 | 2022-11-29 | 江苏拓弘康恒医药有限公司 | 高翻译稳定性BDNF mRNA的设计和制备方法 |
WO2023122752A1 (en) | 2021-12-23 | 2023-06-29 | Renagade Therapeutics Management Inc. | Constrained lipids and methods of use thereof |
WO2023196931A1 (en) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents |
WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
WO2024037578A1 (en) | 2022-08-18 | 2024-02-22 | Suzhou Abogen Biosciences Co., Ltd. | Composition of lipid nanoparticles |
WO2024098360A1 (zh) * | 2022-11-11 | 2024-05-16 | 斯微(上海)生物科技股份有限公司 | 人工核酸分子 |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5908779A (en) | 1993-12-01 | 1999-06-01 | University Of Connecticut | Targeted RNA degradation using nuclear antisense RNA |
WO1998042856A1 (en) | 1997-03-21 | 1998-10-01 | Enzo Therapeutics, Inc., A Fully Owned Subsidiary Of Enzo Biochem, Inc. | Vectors and viral vectors, and packaging cell lines for propagating same |
US6783961B1 (en) * | 1999-02-26 | 2004-08-31 | Genset S.A. | Expressed sequence tags and encoded human proteins |
EP1068312A2 (en) * | 1998-04-09 | 2001-01-17 | Genset | 5' ests and encoded human proteins |
US6423885B1 (en) | 1999-08-13 | 2002-07-23 | Commonwealth Scientific And Industrial Research Organization (Csiro) | Methods for obtaining modified phenotypes in plant cells |
US7700359B2 (en) * | 2000-06-02 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
KR20040055733A (ko) * | 2001-02-28 | 2004-06-26 | 콘드로진 인코포레이티드 | 골관절염에 관련된 조성물 및 방법 |
EP2305699B1 (de) | 2001-06-05 | 2014-08-13 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Impfung gegen Schlafkrankheit, Leishmaniose und Toxoplasmose |
US8021875B2 (en) * | 2001-08-27 | 2011-09-20 | Roche Madison Inc. | Methods for expression of transgenes |
AU2002350039A1 (en) * | 2001-10-29 | 2003-05-12 | Renovis, Inc. | Method for isolating cell-type specific mrnas |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
US9068234B2 (en) * | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
CA2514184C (en) | 2003-01-21 | 2016-04-12 | Ptc Therapeutics, Inc. | Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same |
DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
NZ546554A (en) | 2003-10-10 | 2009-04-30 | Powderject Vaccines Inc | Nucleic acid constructs |
IN2014DN02483A (ru) | 2003-10-24 | 2015-05-15 | Selexis Sa | |
DE102004035227A1 (de) | 2004-07-21 | 2006-02-16 | Curevac Gmbh | mRNA-Gemisch zur Vakzinierung gegen Tumorerkrankungen |
DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
DE102005023170A1 (de) | 2005-05-19 | 2006-11-23 | Curevac Gmbh | Optimierte Formulierung für mRNA |
EP3611266B1 (en) | 2005-08-23 | 2022-11-09 | The Trustees of the University of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
WO2008014979A2 (en) | 2006-07-31 | 2008-02-07 | Curevac Gmbh | NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT |
DE102006035618A1 (de) | 2006-07-31 | 2008-02-07 | Curevac Gmbh | Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz |
DE102006061015A1 (de) | 2006-12-22 | 2008-06-26 | Curevac Gmbh | Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC |
DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
US8101606B2 (en) * | 2007-11-12 | 2012-01-24 | Washington University | Neurofibromin pathway modulators |
EP3346005A1 (en) | 2008-01-31 | 2018-07-11 | CureVac AG | Nucleic acids of formula (i) (nuglxmgnnv)a and derivatives thereof as an immunostimulating agent/adjuvant |
GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
US9539320B2 (en) | 2009-05-15 | 2017-01-10 | Irx Therapeutics, Inc. | Vaccine immunotherapy |
US20110053829A1 (en) | 2009-09-03 | 2011-03-03 | Curevac Gmbh | Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids |
WO2011069529A1 (en) | 2009-12-09 | 2011-06-16 | Curevac Gmbh | Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids |
AU2011285200B2 (en) | 2010-07-30 | 2014-08-21 | CureVac SE | Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation |
WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
WO2013113325A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
WO2013120500A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
SG11201405542UA (en) | 2012-03-27 | 2014-10-30 | Curevac Gmbh | Artificial nucleic acid molecules |
CN104284979B (zh) | 2012-03-27 | 2018-06-08 | 库瑞瓦格股份公司 | 用于提高的蛋白或肽表达的人工核酸分子 |
CN108929880A (zh) | 2012-03-27 | 2018-12-04 | 库瑞瓦格股份公司 | 包含5′toputr的人工核酸分子 |
ES2719598T3 (es) | 2012-05-25 | 2019-07-11 | Curevac Ag | Inmovilización reversible y/o liberación controlada de ácidos nucleicos contenidos en nanopartículas mediante revestimientos poliméricos (biodegradables) |
DK2922554T3 (en) | 2012-11-26 | 2022-05-23 | Modernatx Inc | Terminalt modificeret rna |
CN105473158B (zh) | 2013-08-21 | 2021-04-13 | 库瑞瓦格股份公司 | 呼吸道合胞病毒(rsv)疫苗 |
AU2014310931B2 (en) | 2013-08-21 | 2019-12-19 | CureVac SE | Rabies vaccine |
RU2717986C2 (ru) * | 2013-12-30 | 2020-03-27 | Куревак Аг | Искусственные молекулы нуклеиновой кислоты |
-
2013
- 2013-03-27 CN CN201380016579.4A patent/CN104284979B/zh active Active
- 2013-03-27 WO PCT/EP2013/000937 patent/WO2013143699A1/en active Application Filing
- 2013-03-27 SG SG10201710631RA patent/SG10201710631RA/en unknown
- 2013-03-27 BR BR112014018210A patent/BR112014018210A2/pt not_active Application Discontinuation
- 2013-03-27 MX MX2019002345A patent/MX2019002345A/es unknown
- 2013-03-27 AU AU2013242404A patent/AU2013242404B2/en active Active
- 2013-03-27 JP JP2015502142A patent/JP6185553B2/ja active Active
- 2013-03-27 ES ES13716727.6T patent/ES2654205T3/es active Active
- 2013-03-27 ES ES19171200T patent/ES2969742T3/es active Active
- 2013-03-27 DK DK19171200.9T patent/DK3578659T3/da active
- 2013-03-27 SG SG10201607968WA patent/SG10201607968WA/en unknown
- 2013-03-27 RU RU2014142978A patent/RU2658490C2/ru active
- 2013-03-27 SG SG11201403450VA patent/SG11201403450VA/en unknown
- 2013-03-27 RU RU2018117941A patent/RU2750261C2/ru active
- 2013-03-27 MX MX2014011485A patent/MX362981B/es active IP Right Grant
- 2013-03-27 ES ES17001061T patent/ES2742473T3/es active Active
- 2013-03-27 US US14/388,226 patent/US9683233B2/en active Active
- 2013-03-27 CA CA2859452A patent/CA2859452C/en active Active
- 2013-03-27 DK DK13716727.6T patent/DK2831241T3/da active
- 2013-03-27 KR KR1020147030147A patent/KR102287184B1/ko active IP Right Grant
-
2017
- 2017-05-09 US US15/590,370 patent/US10738306B2/en active Active
- 2017-07-27 JP JP2017145047A patent/JP6700227B2/ja active Active
-
2018
- 2018-11-15 AU AU2018264081A patent/AU2018264081C1/en active Active
-
2020
- 2020-07-04 US US16/920,701 patent/US20200332293A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG10201607968WA (en) | Artificial nucleic acid molecules for improved protein or peptide expression | |
PT4023755T (pt) | Moléculas de ácido nucleico artificiais para uma expressão melhorada de proteína | |
SG10201607962RA (en) | Artificial nucleic acid molecules | |
HK1206636A1 (en) | Modified polynucleotides for the production of oncology-related proteins and peptides | |
SG11201603144QA (en) | Artificial nucleic acid molecules | |
IL230918A0 (en) | Modified proteins and peptides | |
HK1209779A1 (en) | Transposition-mediated identification of specific binding or functional proteins | |
EP2771033A4 (en) | PROTEIN FORMULATIONS CONTAINING AMINO ACIDS | |
ZA201305611B (en) | Pesticidal nucleic acids and proteins and uses thereof | |
EP2929045A4 (en) | PROTEIN EXPRESSION REINFORCING POLYPEPTIDES | |
EP2883882A4 (en) | PROCESS FOR PURIFYING PROTEINS | |
EP2900697A4 (en) | PEPTIDE DIRECTED PROTEIN INACTIVATION | |
IL239285A0 (en) | Yogurts with high protein | |
EP2566333A4 (en) | IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS | |
PL2858490T3 (pl) | Rekombinowane elementy dna do ekspresji rekombinowanych białek w owadach | |
HK1205186A1 (en) | Method for the expression of polypeptides using modified nucleic acids | |
DK3260541T3 (da) | Kunstige nukleinsyremolekyler til forbedret protein- eller preptidekspression | |
SG11201404180RA (en) | Cho-gmt recombinant protein expression | |
EP2829603A4 (en) | PROTEIN REGISTRATION PROCEDURES | |
GB201213672D0 (en) | Protein | |
ZA201504016B (en) | Biocomposite materials derived from animal protein | |
GB201214974D0 (en) | Avian proteins, nucleic acids and uses thereof | |
GB201200743D0 (en) | Protein bridges | |
GB201121226D0 (en) | Modified proteins and peptides | |
GB201121233D0 (en) | Modified proteins and peptides |